TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of VZV-specific ELISPOT Assay for Predicting VZV Infection in Kidney Transplant Recipients (AVE-KT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age 16 years or more~* agree with written informed consent~* WBC count 2000/uL or more~Exclusion Criteria:~* no exclusion criteria

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- high VZV ELISPOT results (Type: None): high spot counts in ELISPOT
- low VZV ELISPOT results (Type: None): low spot counts in ELISPOT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: TMS Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers: R-baclofen Effects in Normal Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18-30~* IQ: higher than 85~* Normal physical examination~Exclusion Criteria~* significant medical problems~* ongoing medications~* All female participants are required to have a negative pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- sugar pill (Type: PLACEBO_COMPARATOR): placebo administered under double blind conditions
- 3 mg of R-baclofen (Type: EXPERIMENTAL): 3 mg of R-Baclofen administered double blind
- 10 mg of R-baclofen (Type: EXPERIMENTAL): 10 mg of R-baclofen administered double-blind
- 25 mg of R-baclofen (Type: EXPERIMENTAL): 25 mg of R-baclofen administered double blind
- second sugar pill (Type: PLACEBO_COMPARATOR): the second placebo administered double blind

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Spray Cryotherapy for Esophageal Cancer (ICE-CANCER)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* T1aN0M0 esophageal cancer (tumor invades no deeper than lamina propria or muscularis mucosa, no regional lymph node or distant metastases), with the following minimum diagnostic workup:~* History/physical exam within 6 weeks prior to enrollment~* PET and CT scan of the chest and abdomen within 12 weeks prior to enrollment~* Endoscopy with histology or cytology confirming carcinoma~* Endoscopic ultrasound (EUS) with evaluation of the esophageal wall, mediastinum, and upper abdomen for evidence of abnormal lymph nodes. Suspicious lymph nodes will undergo EUS-guided fine needle aspiration if appropriate, as determined by the investigator.~* Endoscopic resection of focal lesions with histologic confirmation of positive deep margin or residual cancer within the esophagus~* Not a candidate for or refuses conventional therapies (surgery, radiation, chemotherapy, endoscopic resection) as determined by evaluation by the investigator, discussion with the patient, and review in Thoracic or Gastrointestinal Tumor Board.~* For females: not pregnant (negative pregnancy test within 14 days of starting study treatment), on acceptable means of contraception (oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device or tubal ligation), or not of child bearing potential. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.~* 18 years of age or older~* ECOG Performance Status 0 - 2~Exclusion Criteria:~* Medically unfit or other contraindication to tolerate upper endoscopy with ablation~* Contraindication to endoscopic spray cryotherapy as outlined in the directions for use for the device~* Other malignancy (except nonmelanoma skin cancer) within the past 1 year~* Co-morbid illness expected to cause death within 6 months~* Esophageal stricture preventing passage of endoscope or catheter~* Concurrent enrollment in an investigational drug or device trial that clinically interferes with this study's endpoints throughout the study~* Inability to provide informed consent or comply with this protocol~* Concurrent or previous cancer therapy for current esophageal malignancy by esophagectomy, chemotherapy, radiation therapy, and photodynamic therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cryotherapy (Type: EXPERIMENTAL): Liquid nitrogen spray cryotherapy with the truFreeze device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Liposomal Bupivacaine Infiltration vs Continuous Perineural Ropivacaine Infusion for Post-operative Pain After Total Shoulder Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Presenting to University of Maryland Rehabilitation and Orthopaedic Institute for total shoulder arthroplasty (TSA) or reverse TSA~* Primary language is English~Exclusion Criteria:~* Allergy to either ropivacaine or bupivacaine~* On chronic opioid therapy at the time of evaluation~* Pre-existing neurologic condition which precludes the use of regional anesthesia~* Unable to provide consent as determined by the operating surgeons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TSA - Liposomal Bupivacaine Infiltration (Type: ACTIVE_COMPARATOR): Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension for postoperative analgesia after total shoulder arthroplasty (TSA).
- Reverse TSA - Liposomal Bupivacaine Infiltration (Type: ACTIVE_COMPARATOR): Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension for postoperative analgesia after reverse total shoulder arthroplasty (TSA).
- TSA - Continuous Perineural Ropivacaine Infusion (Type: ACTIVE_COMPARATOR): Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine for postoperative analgesia after TSA.
- Reverse TSA - Continuous Perineural Ropivacaine Infusion (Type: ACTIVE_COMPARATOR): Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine for postoperative analgesia after reverse TSA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Seasonal Allergic Rhinitis and Driving Ability

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* outpatients with seasonal allergic rhinitis~* a valid driver's licence~* written informed consent~* a T5SS score \>8 during the allergic season and \<3 in winter~Exclusion Criteria:~* use of medication or medical conditions that are known to affect driving ability~* associated ENT disease or asthma

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): 1 week of treatment discontinuation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treating Alzheimer's and Dementia With D-ribose

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of Alzheimer's and/or dementia with a Mini Mental Status Exam ( MMSE) score over 12 or being ambulatory and able to travel outside the home with assistance.~* Must have a caregiver living with them.~Exclusion Criteria:~* Overt and severe causes of secondary dementia such as metastatic brain cancers, or severe overt infectious encephalopathies or severe autoimmune illness.~* Also, severe life threatening illnesses which would make them unlikely to be alive after 6-12 months.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment with d-ribose (Type: EXPERIMENTAL): Treatment with ribose 5 gm TID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Thorax Enlarging Surgery: a Novel Surgical Approach to Emphysema

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~patients with end-stage emphysema and~* Disabling dyspnea~* GOLD III or IV~* Residual volume \> 200% predicted~* Total Lung capacity \> 120% predicted~* RV/TLC \> 0.6~* Resting CO2 \< 50 mmHg~* diffusion capacity \> 20% predicted~* age \< 70 years~Exclusion Criteria:~* previous sternotomy~* contraindication of general anesthesia~* chronic treatment with corticosteroids~* any tobacco use within 6 months~* candidates for lung volume reduction surgery or lung transplantation

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Experimental surgical intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Type 2 Diabetes Mellitus by Duodenal Exclusion Associated With Omentectomy: Clinical and Hormonal Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 to 60 years.~* BMI between 25 and 29,9 kg/m².~* Weight variance less than 5% in the last 3 months.~* Previous diagnosis of diabetes type 2.~* Insulin requirement, alone or along with oral agents~* Capacity to understand the procedures of the study.~* To agree voluntarily to participate of the study, signing an informed consent.~Exclusion Criteria:~* Positive Anti-GAD antibodies~* Laboratorial signal of probable failure of insulin production, i. e., seric peptide C lesser than 1 ng/mL.~* History of hepatic disease like cirrhosis or chronic active hepatitis.~* Kidney dysfunction (creatinine \> 1,4 mg/dl in women and \> 1,5 mg/dl in men).~* Hepatic dysfunction: ALT and/or AST 3x above upper normal limit.~* Recent history of neoplasia (\< 5 years).~* Use of oral or injectable corticosteroids for more than consecutive 14 days in the last three months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Duodenal exclusion plus total omentectomy
- 2 (Type: ACTIVE_COMPARATOR): Duodenal exclusion without omentectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Radiofrequency Ablation: Treatment for Posterior Element Pain From Vertebral Compression Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
I• Inclusion~* 18-90 years old~* Male or female~* Age of fracture greater than or equal to 6 weeks~* Single Level Vertebral Compression Fracture~* Vertebral compression fracture Thoraic-9 to Lumbar-5~* NRS \>6/10~  • Exclusion~* \<18 or \>90 yo~* Uncorrectable Coagulopathy~* Multiple Level Vertebral Compression Fractures~* Surgery within 60 days of presentation~* Active infection~* Rhuematologic disease~* Significant neurologic deficit~* Radicular pain~* Chronic low back pain in last year~* Inability to give consent~* Cognitive impairment~* Patients with Ongoing Litigation or Worker's Compensation Cases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: ACTIVE_COMPARATOR): The control group will receive usual care for treatment of vertebral compression fractures, which will consist of but not limited to: physical therapy, opioids, NSAIDs, acetaminophen and bisphosphonates as indicated. They will have the option of crossing over (see Crossover Group) at twelve weeks.
- Treatment Group (Type: ACTIVE_COMPARATOR): The treatment group will receive usual care for treatment and the treatment procedure comprised of the Medial Branch Block and Radiofrequency Ablation. In cases where a medial branch nerve block has confirmed there is pain relief, a radiofrequency ablation is considered. These patients will continue their usual care therapy as well.
- Crossover Group (Type: ACTIVE_COMPARATOR): This group will comprise of patients within the control group who after 12 weeks of usual therapy will have the option of crossing over to the treatment group. Once crossed over, their treatment and course and measurements will be identical to that of the treatment group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI 20 - 27kg/m2~* Caucasians~* Healthy volunteers~Exclusion Criteria:~* Pregnancy/lactation period~* Drug allergy~* Acute and chronic diseases~* Taking medication~* Abuse of drugs, alcohol etc.~* Smoker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Metoclopramide (Type: ACTIVE_COMPARATOR): Metoclopramide treatment
- Diphenhydramine (Type: ACTIVE_COMPARATOR): Diphenhydramine treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years or minimum age as required by local regulations.~* Patient has been thoroughly informed about this registry and signed Informed Consent Form.~* Patient with true resistant hypertension defined as:~  * Office systolic BP higher than 160 or 150mmHg in case of type 2 diabetes~ * Ambulatory BP with average BP\>130mmHg or mean daytime\>135mmHg in more than 70% of the measurements.~* Patients should be on stable hypertension therapy for at least 8 weeks before procedure, including spironolactone if they are supposed to be respondent as indicated by the specialized center/excellence unit on hypertension.~Exclusion Criteria:~* Previous renal artery intervention (balloon angioplasty or stenting).~* Evidence of renal artery atherosclerosis (defined as a renal artery stenosis \>50%).~* Main renal arteries of less than 4mm diameter or less than 20mm in length.~* Presence of multiple main renal arteries in either kidney.~* Estimated glomerular filtration rate \<45ml/min per 1,73m2~* Recent myocardial infarction, unstable angina pectoris or cerebrovascular accident within the past 3-6 months.~* False resistant hypertension (pseudo resistance) by using 24h ambulatory BP monitoring (ABPM).~* Secondary arterial hypertension.~* Pregnancy.~* There is another pathological process with well-known life expectancy of less than 5 years.~* Patient unable to do correct FU.~* Unable to take correct ambulatory BP.~* Primary hyperaldosteronism.~* Known lack of adherence to medical treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Medrol Dosepak Taper for Delayed Post-op Recovery After TKA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient undergoing primary TKA with a diagnosis of osteoarthritis~* ≥ 18 years old~* ROM \<90° by 3 weeks postoperatively without improvement to \>90° by 6 weeks~* Requiring a 30-pill oxycodone refill~* NSAID allergy~* Thigh circumference discrepancy \>2cm between legs from 3 to 6 weeks~* Defense and Veterans Pain Rating Scale (DVPRS) \> 5 between 3 and 6 weeks~* Willingness to undergo randomization~Exclusion Criteria:~* Reported chronic corticosteroid or opiate use~* Suspected or confirmed periprosthetic joint infection~* Revision TKA~* Primary diagnosis other than osteoarthritis, including avascular necrosis, fracture, or post-traumatic arthritis~* American Society of Anesthesiologists (ASA) score ≥ 4~* Reported history of liver or renal disease~* Uncontrolled diabetes~* Immunosuppression~* ≤ 18 years old~* Inability to take oral medications~* Unable to provide consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Methylprednisolone taper (Type: ACTIVE_COMPARATOR): 21 x 4mg tablets at 6 weeks, qualifying for MUA if ROM \<90° at 8 weeks
- Placebo taper (Type: PLACEBO_COMPARATOR): 21 sugar tablets at 6 weeks with standard management, qualifying for MUA if ROM \<90° at 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Second Generation Designer T Cells in Colorectal Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must have cancer of the colon or rectum~* Must have metastatic or unresectable locally advanced disease~* Tumor must express CEA by tumor staining or by elevated serum CEA (\>10 ng/ml)~* Must have measurable disease radiologically or by physical exam~* Must have failed potentially curative standard therapy~* Must be 18 years of age or older~* Good performance status (PS 0-1)~Exclusion Criteria:~* Requiring systemic steroids~* Serious medical conditions~* Concurrent malignancies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gene Modified T Cells (Type: EXPERIMENTAL): Modified T cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women, age 30-75, with breast cancer who are admitted for a lumpectomy or mastectomy at Herlev Hospital~* ASA score I-III~* No sign of depression measured my Major Depression Inventory (MDI)~* Not pregnant~Exclusion Criteria:~* Neoadjuvant chemotherapy~* Treatment with SSRI, Warfarin or other anticoagulants (except 75 mg ASA daily), MAO inhibitors or calcium blockers~* Rotor or Dubin-Johnson syndrome~* Epilepsy~* Known allergic reaction to melatonin~* Known and treated sleep apnea~* Diabetes Mellitus - insulin treated~* Ongoing or previous medically treated depression or bipolar disorder~* Known autoimmune diseases - systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and sclerose~* Incompensated liver cirrhosis~* Severe kidney disease~* Previous or current cancer~* Known medically treated sleep-disorder (insomnia, restless legs etc)~* Shift-work and night-work~* Daily alcohol intake of more than 5 units~* Pre-operative treatment with psychopharmacological drugs, opioids or anxiolytics (including all sleeping pills)~* Predicted bad compliance~* Pregnant or breast-feeding~* Pre-operative Mini Mental State Evaluation (MMSE) score less than 24

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Melatonin (Type: ACTIVE_COMPARATOR): 6 mg oral melatonin daily
- Placebo (Type: PLACEBO_COMPARATOR): 6 mg oral placebo daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility